European Commission Approves Label Expansion for Ionis and Sobi's Tryngolza
The European Commission has granted a label expansion for Tryngolza, an RNA-targeting lipid-lowering therapy developed by Ionis Pharmaceuticals (IONS) and marketed in partnership with Swedish firm Sobi (BIOVF/SWOBY). In addition to its current authorization for treating familial chylomicronemia syndrome, the expanded approval broadens the therapeutic application of the drug. This regulatory milestone strengthens the commercial positioning of the partnership between Ionis and Sobi within the European market.

Topics: drug approval label expansion RNA therapy